No annual revenue total was found in ORIC PHARMACEUTICALS, INC.'s SEC filings.
Oric Pharmaceuticals, Inc. (ORIC) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$111.7 million. As of Jun 30, 2026 it held $387.6 million in cash and investments and $3.3 million in total debt.
Revenue
—
Net income (TTM)
$-140.35M
-2.3% vs year-ago TTM
Operating cash flow (TTM)
$-111.64M
+7.1% vs year-ago TTM
Free cash flow (TTM)
$-112.26M
+7.5% vs year-ago TTM
EPS (TTM)
$-1.35
+28.4% vs year-ago TTM
Dividend per share
None
Shares outstanding
100.36M
+41.3% vs prior year
Net cash
$384.24M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ORIC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1796280
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$143.0M | -$142.9M | -$110.8M | -$91.8M | -$78.9M |
| Net income | -$129.5M | -$127.8M | -$100.7M | -$89.1M | -$78.7M |
| Diluted EPS | -$1.47 | -$1.83 | -$1.96 | -$2.25 | — |
| Operating cash flow | -$111.0M | -$112.7M | -$85.7M | -$75.1M | -$59.5M |
| Free cash flow | -$111.7M | -$113.8M | -$86.5M | -$77.2M | -$60.5M |
| Total assets | $408.9M | $274.1M | $252.0M | $247.2M | $298.6M |
| Total liabilities | $24.5M | $31.0M | $27.9M | $24.8M | $25.7M |
| Stockholders' equity | $384.4M | $243.1M | $224.1M | $222.4M | $273.0M |
| Cash and investments | $392.2M | $256.0M | $235.0M | $228.2M | $280.4M |
| Total debt | $7.4M | $9.4M | $10.2M | $12.1M | $22.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 23, 2026 | Oct 23, 2026 |
| 10-Q | Quarterly report | Aug 3, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 3, 2026 | Aug 3, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 30, 2026 | Jul 28, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 22, 2026 | Jun 18, 2026 |
| 10-Q | Quarterly report | May 4, 2026 | Mar 31, 2026 |
All 423 Oric Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.